Unknown

Dataset Information

0

Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development.

ABSTRACT: Despite failures in late-phase trials, the pipeline of medications for Alzheimer's disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.

SUBMITTER: Kish T 

PROVIDER: S-EPMC5871244 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development.

Kish Troy T  

P & T : a peer-reviewed journal for formulary management 20180401 4

Despite failures in late-phase trials, the pipeline of medications for Alzheimer's disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development. ...[more]

Similar Datasets

Unknown Drug development for Alzheimer's disease: recent progress.
| S-EPMC3214787 | biostudies-other
Unknown Alzheimer's disease drug development pipeline: 2020.
| S-EPMC7364858 | biostudies-literature
Unknown Alzheimer's disease drug development pipeline: 2017.
| S-EPMC5651419 | biostudies-literature
Unknown Alzheimer's disease drug development pipeline: 2018.
| S-EPMC6021548 | biostudies-literature
Unknown Alzheimer's disease drug development pipeline: 2021.
| S-EPMC8145448 | biostudies-literature
Unknown The Alzheimer's disease drug development landscape.
| S-EPMC8582156 | biostudies-literature
Unknown Alzheimer's disease drug development pipeline: 2019.
| S-EPMC6617248 | biostudies-literature
Unknown Repurposed agents in the Alzheimer's disease drug development pipeline.
| S-EPMC7433208 | biostudies-literature
Unknown Intense Focus of Alveolar Echinococcosis, South Kyrgyzstan.
| S-EPMC6004877 | biostudies-literature
Unknown Drug treatments in Alzheimer's disease.
| S-EPMC5922703 | biostudies-other